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Abstract 
A simple, sensitive and rapid assay method has been developed and validated for the estimation of 
enzalutamide, N-desmethylenzalutamide (active metabolite of enzalutamide), darolutamide and ORM-
15341 (active metabolite of darolutamide) on mice dried blood spots (DBS) using liquid chromatography 
coupled to tandem mass spectrometry with electro spray ionization in the positive-ion mode. The method 
utilizes liquid extraction of enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 from 3 
mm punched disks from DBS cards (spiked or study samples). The extracted sample was chromatographed 
using an isocratic mobile phase (0.2 % formic acid : acetonitrile; 30:70, v/v) on an Atlantis dC18 column. 
The total run time was 2.5 min. The MS/MS ion transitions monitored were m/z 465 → m/z 209, m/z 451 →  
m/z 195, m/z 399 → m/z 178, m/z 397 →  m/z 194 and m/z 481 → m/z 453 for enzalutamide, N-desmethyl-
enzalutamide, darolutamide, ORM-15341 and the IS (apalutamide-d3), respectively. Method validation was 
performed as per regulatory guideline. The assay had a good linearity over the range of 0.93-2000 ng/mL. 
The intra- and inter-batch accuracy and precision (%RE & RSD) across quality controls met the acceptance 
criteria for all the analytes. Stability studies showed that all the analytes were stable on DBS cards for one 
month. This novel method has been applied to analyze the DBS samples of enzalutamide, N-
desmethylenzalutamide, darolutamide and ORM-15341 obtained from a pharmacokinetic study in mice. 
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Introduction 
Despite therapeutic advances, prostate adenocarcinoma is the highly prevalent cancer in men and 
responsible for 20 % of cancer related deaths in the Western world [1]. Initial approach to cure the 
localized prostate cancer is through radiation therapy or surgical castration or treatment with first-
generation anti-androgens (flutamide, nilutamide, bicalutamide etc.) [2]. However, despite an initial 
response, most patients develop a most aggressive form of disease called metastatic castration-resistant 
prostate cancer (mCRPC) that is associated with tumor progression and survival less than 18-24 months [3]. 
Consequently, in recent years, new therapy options for mCRPC with different mechanisms of action have 
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become available like targeting androgen receptor signalling such as CYP17A1 inhibitor (abiraterone 
acetate) [4] and a second-generation androgen receptor antagonist (enzalutamide, apalutamide and 




; Fig. 1) was recently approved for the treatment of mCRPC [5,8]. Enzalutamide is 
metabolized by CYP3A4 and 2C8 to produce an active circulatory metabolite, N-desmethylenzalutamide 
(Fig. 1), which has similar in vitro potency to enzalutamide [9,10]. Darolutamide (ODM-201; Fig. 1) is a 
novel, orally active, second-generation non-steroidal anti-androgen. It is an equi-mixture of two 
pharmacologically active diastereomers namely ORM-16497 and ORM-16555. Darolutamide undergoes 
extensive Phase-I metabolism and produces circulatory metabolite i.e., ORM-15341 (Fig. 1). ORM-16497, 
ORM-16555 and ORM-15341 are fully antagonist against bicalutamide, hydroxyflutamide, enzalutamide 
and ARN-509 mutants [11,12]. Unlike enzalutamide and apalutamide, penetration of darolutamide and 
ORM-15341 into brain is negligible (in preclinical species) suggests that low risk of causing seizures in 
patients [7]. In clinic, darolutamide was tolerated up to 1800 mg and no dose-limiting toxic effects were 
reported. It was reported that ORM-15341 plasma concentrations were higher than sum of ORM-16497 
and ORM-16555 plasma concentrations [13]. Currently Phase-III clinical trials are being conducted with 





















































ORM-15341 Apalutamide-d3 (IS) 
Figure 1. Structural representation of enzalutamide, N-desmethylenzalutamide, darolutamide, ORM-15341 
and apalutamide-d3 (IS) 
In contemporary literature few LC-MS/MS bioanalytical methods were reported for quantification of 
enzalutamide alone [14] or along with its metabolites [15,16] and other anti-androgens [17-19] or 
anticancer drugs [20] in various biological matrices (preclinical species plasma/tissues and human plasma). 
Similarly darolutamide and ORM-15341 quantification in mice plasma was reported post-administration of 
darolutamide [21] and along with other second-generation non-steroidal anti-androgens (enzalutamide, 
apalutamide) [20] using conventional achiral columns on LC-MS/MS. Apart from these achiral methods, 
two chiral LC-MS/MS methods for quantification darolutamide diastereomers alone [22] or along with its 
metabolite [23] were reported in recent times.  
Traditional bioanalysis of samples from preclinical species and clinical trials relies on collection of blood 
or its products (serum and plasma). Collection of blood in a preclinical set up especially with rodents, 
pediatric cases and new-borns is a challenge and not possible to draw blood samples at multiple time 
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points. This will force researcher to adopt sparse sampling, which limits the researcher to study the 
pharmacokinetics from individual animal/neonate. Traditional samples are normally shipped on dry ice 
from one place to other, which incurs shipping and handling costs. Over the wet sampling 
(blood/plasma/serum) techniques, dried blood spots (DBS) method offers several advantages like reduced 
blood/plasma/serum volume per time point, ease and safety in handling, potential cost saving in storage 
and shipment at ambient room temperature, less sample processing time and increase in throughput etc. 
[24].  
To the best of our knowledge, simultaneous method for the determination of enzalutamide, N-
desmethylenzalutamide, darolutamide and ORM-15341 on mice DBS has not been reported in the 
literature. For this purpose, the present study is aimed to develop and validate a simple and rapid LC-
MS/MS method for simultaneous quantification of enzalutamide, N-desmethylenzalutamide, darolutamide 
and ORM-15341 on mice DBS without compromising on sensitivity. The validated method was successfully 
used in a mice pharmacokinetic study following intravenous administration of enzalutamide and 
darolutamide at 1.0 mg/kg dose.  
Materials and methods  
Materials 
 Enzalutamide (purity: >98.3 %) and N-desmethylenzalutamide (purity: >99.6 %) were purchased 
from BioOrganics, Bangalore, India. Darolutamide (purity: 98 %) was procured from Angene International 
Limited, China. ORM-15341 (purity: 99.4 %) and apalutamide-d3 (purity: 99.5 %; Fig. 1) were synthesized by 
the Medicinal chemistry group, Jubilant Biosys (Bangalore, India) using literature information [25,26] and 
characterized using chromatographic (HPLC, LC-MS/MS) and spectral techniques (IR, UV, Mass, 1H and 
13C-NMR) by the Analytical research group, Jubilant Biosys. HPLC-grade acetonitrile, methanol, methyl 
tert-butyl ether (TBME) and ethyl acetate were purchased from Rankem, New Delhi, India. Whatman FTA 
DMPK card C DBS cards were purchased from GE, Bangalore. Silica gel sachets and sealable plastic bags for 
the storage of DBS cards were purchased from local market. 
Instrumentation and chromatographic conditions  
A Shimadzu VP (Shimadzu, Japan) LC system equipped with degasser (G1379A), quaternary pump 
(10ADvp), column oven (CTO-10ASvp), auto-sampler (SIL-HTC) along with system controller (SCL-10Avp) 
was used to inject 5.0 µL aliquots of the processed samples on an Atlantis dC18 column (50 x 4.6 mm, 
3 µm; Waters, Milford, MA, USA), which was kept at ambient temperature (24 ± 1 °C). The isocratic mobile 
phase, a mixture of 0.2 % formic acid : acetonitrile (30:70, v/v) was filtered through a 0.45 µm membrane 
filter (XI5522050) (Millipore, USA or equivalent) and then degassed ultrasonically for 5 min was delivered 
at a flow rate of 0.8 mL/min (with splitter 50 %) into the mass spectrometer electro spray ionization 
chamber.  
Quantitation was achieved by MS/MS detection in positive ion mode for the analytes and the IS using 
Sciex (Foster City, CA, USA) API-6500 mass spectrometer, equipped with a Turboionspray interface at 
500 °C and 5500 V ion spray voltage. The common parameters, i.e. curtain gas (CUR), nebulizer gas (GS1), 
auxiliary gas (GS2) and collision gas (CAD) were set at 55, 55, 65 and 10 psi, respectively. The compounds 
parameters, i.e. declustering potential (DP), collision energy (CE), collision exit potential (CXP) and entrance 
potential (EP) for the analytes and the IS are shown in Table 1. The dwell time was 100 msec. Quantitation 
of enzalutamide, N-desmethylenzalutamide, darolutamide, ORM-15341 and the IS was achieved by 
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monitoring the precursor Q1 → Q3 ions at m/z 465→209, 451→195, 399→178, 397→194 and 481→453, 
respectively. Both Q1 and Q3 quadruples were set on unit resolution. The analytical data was processed by 
Analyst software (version 1.6.2). 
Table 1. Optimized mass spectrometry parameters for analytes and the IS 
 in Volts 
Analyte DP EP CE CXP 
Enzalutamide  80 10 41 12 
N-Desmethyl-
enzalutamide 
80 10 41 12 
Darolutamide 91 10 31 30 
ORM-15341 60 10 27 12 
Apalutamide-d3 (IS) 100 10 33 12 
DP: declustering potential; EP: entrance potential; CE: collision energy and CXP: collision cell exit potential 
Preparation of stock and standard solutions  
Primary stock solutions of enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 for 
preparation of calibration curve (CC) and quality control (QC) samples were prepared from separate 
weighing. Individual primary stock solution of all the analytes at 200 µg/mL were prepared in 
DMSO:methanol (0.2:99.8, v/v). Similarly the primary stock solution of the IS (200 µg/mL) was prepared in 
methanol. The primary stock solutions of enzalutamide, N-desmethylenzalutamide, darolutamide, ORM-
15341 and the IS were stored at -20 °C, which were found to be stable for one month. The primary stock 
solutions of enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 were successively 
diluted in DMSO:methanol (0.2:99.8, v/v) to prepare secondary stock and working stock solutions to 
prepare CC and QC samples. Working stock solutions were stored approximately at 4 °C for 30 days and 
found to be stable. A working stock of the IS solution (25 ng/mL) was prepared in methanol. Samples for 
the determination of precision and accuracy were prepared by spiking control mice blood in bulk with 
mixed working stock solution of enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 
at appropriate concentrations 0.93 ng/mL (lower limit of quantitation quality control, LLOQ QC), 2.80 
ng/mL (low quality control, LQC), 853 ng/mL (medium quality control, MQC) and 1493 ng/mL (high quality 
control, HQC). DBS cards were prepared (as mentioned in Blood spotting section) at each QC level and 
were stored at -80 ± 10 °C until analysis. 
Blood spotting  
The DBS cards were prepared from freshly drawn whole blood, harvested on the same day by spotting 
25 µL of the respective spiked CC/QC or whole blood from the enzalutamide, N-desmethylenzalutamide, 
darolutamide and ORM-15341 treated mouse onto sampling paper using a calibrated pipette. The samples 
were left to dry at room temperature least 3 h before storing at controlled room temperature (24 ± 1 °C) 
until analysis. 
Recovery 
The efficiency of enzalutamide, N-desmethylenzalutamide, darolutamide, ORM-15341 and the IS 
extraction from DBS samples was determined by comparing the responses of the analyte extracted from 
replicate QC samples (n = 6) with the response of analyte from neat standards at equivalent concentrations 
by liquid extraction process. Recovery of enzalutamide, N-desmethylenzalutamide, darolutamide and 
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ORM-15341 was determined at LQC (2.80 ng/mL) and HQC (1493 ng/mL) concentrations. Recovery of the 
IS was determined at a single concentration of 25 ng/mL. Samples were prepared by punching a 3 mm 
diameter disk from the centre of the DBS using a hole puncher (Harri-Micro-Punch

, 3 mm circle) into a 2.0 
mL microcentrifuge tube using the 200 µL of extraction solvents viz., TBME, ethyl acetate, methanol, 
acetonitrile, methanol/acetonitrile:water (in different ratios). 
Sample preparation 
To each DBS card (3 mm) in a glass tube, 200 µL of water was added vortex mixed for 10 min and 
sonicated for 10 min at room temperature. Post sonication 200 µL of acetonitrile enriched with the IS 
(25 ng/mL) was added vortex mixed for 10 min followed by centrifugation 10 min. Clear supernatant 
(200 µL) was separated and transferred into a HPLC vial for injection and 5.0 µL was injected onto LC-
MS/MS system.  
Method validation 
The validation experiments were performed in accordance with the US Food and Drug Administration 
guideline [27]. 
Selectivity  
Selectivity of the method was determined by determining the presence of interfering peaks from six 
individual drug-free mice DBS samples at the retention times of enzalutamide, N-desmethylenzalutamide, 
darolutamide, ORM-15341 and the IS. 
Limit of quantification and carry over 
The LLOQ was determined as the concentration that has a precision of <20 % of the relative standard 
deviation and accuracy between 80-120 % of the theoretical value. The auto-injector carryover was 
determined by injecting the highest calibration standard, followed by injection of blank samples. The 
response of the blanks was then compared to that of the LLOQ. 
Calibration curve 
Calibration samples (for all the analytes) were prepared on each validation day. Peak area ratios of each 
analyte to that of IS were used for all calculations. A least squares linear regression (1/X2 weighting factor) 
of eight non-zero samples was used to define the calibration curve. 
Precision and accuracy 
The precision and accuracy of the method were evaluated by measuring the four QC samples (LLOQ QC, 
LQC, MQC and HQC), which were prepared on each validation day (n = 6 each). Inter-day precision was 
assessed on three separate days. Inter- and intra-day precisions were determined by calculating percent 
relative standard deviation (%RSD) that should be <15 % for all the QC levels except for LLOQ QC where it 
should be <20 %. The inter- and intra-day accuracy expressed as percent relative error (%RE) was 
calculated by comparing the measured concentration with the nominal value and deviation was limited 
within ±15 % except for LLOQ QC where it should be <20 %. 
Matrix effect 
Matrix effect for enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 was assessed 
by comparing each analyte mean peak areas at LQC and HQC concentration after with the mean peak areas 
for post extracted DBS samples spiked with analyte at equivalent concentrations. Matrix effect for the IS 
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was assessed at single concentration (25 ng/mL). 
Stability 
The stability of enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 was assessed 
at LQC and HQC levels in six replicates under all storage conditions. Freeze-thaw stability was performed 
following three freeze-thaw cycles was evaluated (DBS cards were stored in -80 ± 10 °C between 
freeze/thaw cycles). Short-term temperature stability was assessed by analyzing samples that had been 
kept at ambient temperature (25 ± 1 °C) for 7 days. Long-term stability was performed by analyzing 
samples that had been stored at -80 ± 10 °C for 30 days. The stability of enzalutamide, N-desmethyl-
enzalutamide, darolutamide, ORM-15341 and the IS in the injection solvent was determined periodically by 
injecting replicate preparations of processed DBS samples for up to 24 h (in the auto-sampler at 5 °C) after 
the initial injection. 
Dilution effect 
To evaluate the effect of dilution over the calibration range, the accuracy and precision of dilution 
control samples at 10,000 ng/mL (n = 6; 5 times of the ULOQ) were assessed by performing a 10-fold 
dilution. 
Influence of hematocrit  
Hematocrit (Hct) has a significant effect on the viscosity of the blood, which influences the flux and 
diffusion properties of the blood through DBS card used for sample collection. It can directly affect the 
accuracy of the analysis in DBS samples. Hct is normally about 43-48 for Balb/C mice (in house data). The 
effect of the Hct on analytical performance was investigated by measuring LQCs and HQCs spiked in six 
different sources of blood adjusted with plasma to obtain values at 25, 35 and 45 % haematocrit that were 
analysed with calibrators prepared in blood at standard fixed 40 % Hct. The relative error of ±15 % and 
precision of ≤15 % was considered acceptable. Hematocrits were measured using Mindray BC-5000Vet. 
Pharmacokinetic study  
All the animal experiments were approved by Institutional Animal Ethical Committee 
(IAEC/JDC/2017/133). Male Balb/C mice (n = 12) purchased from Vivo Biotech, Hyderabad were housed in 
Jubilant Biosys animal house facility in a temperature (22 ± 1 °C) and humidity (30-70 %) controlled room 
(15 air changes/h) with a 12:12 h light:dark cycles, had free access to rodent feed (Altromin Spezialfutter 
GmbH & Co. KG., Im Seelenkamp 20, D-32791, Lage, Germany) and water for one week before using for 
experimental purpose. Following ~4 h fast (during the fasting period animals had free access to water) mice 
(25-32 g) received enzalutamide and darolutamide intravenously [5 % DMSO, 5 % Solutol:absolute alcohol 
(1:1, v/v) and 90 % of normal saline; strength: 0.1 mg/mL; dose volume: 10 mL/kg] as a cassette dose at 1.0 
mg/kg. Post-dosing serial blood samples (25 µL, sparse sampling was done and at each time point three 
mice were used for blood sampling) were collected at regular intervals using micropipettes (Microcaps®; 
catalogue number: 1-000-0500) through tail vein into polypropylene tubes containing K2.EDTA solution as 
an anti-coagulant 0.12, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144 and 168 h and spotted onto the cards 
and air dried at room temperature for 3 h before storing at controlled room temperature (25 °C) until 
analysis. Animals were allowed to eat feed 2 h post-dose of enzalutamide and darolutamide.  
The criteria for acceptance of the analytical runs encompassed the following: (i) 67 % of the QC samples 
accuracy must be within 85-115 % of the nominal concentration (ii) not less than 50 % at each QC 
concentration level must meet the acceptance criteria [27]. Blood concentration versus time data of 
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enzalutamide, darolutamide and ORM-15341 was analyzed by non-compartmental method using Phoenix 
WinNonlin Version 7.0. 
Results  
MS/MS conditions and chromatography 
The optimum LC-MS/MS mobile phase was determined through several trials to achieve good 
resolution and symmetric peak shapes for the analytes and the IS in short run time. To obtain good 
separation, resolution and peak shape for enzalutamide, N-desmethylenzalutamide, darolutamide, ORM-
15341 and the IS isocratic elution was used at a flow rate 0.8 mL/min. Among the several commercial 
columns (Inertsil, Atlantis, Kromasil, Hypersil etc.) tested, an Atlantis dC18 column (50 x 4.6 mm, 5 µm) was 
selected because it provided symmetric peaks and baseline separation of enzalutamide, N-desmethyl-
enzalutamide, darolutamide, ORM-15341 and the IS within 2.5 min run time. The MS/MS ion transitions 
monitored were m/z 465→209, m/z 451→195, m/z 399→178, m/z 397→194 and m/z 481→453 for 
enzalutamide, N-desmethylenzalutamide, darolutamide, ORM-15341 and the IS, respectively for 
quantitation. The retention time of enzalutamide, N-desmethylenzalutamide, darolutamide, ORM-15341 
and the IS was 1.32, 1.23, 1.01, 1.12 and 1.43 min, respectively. The total run time is 2.5 min (Fig. 2a-d). 
Method validation 
Selectivity 
As shown in Figures 2a-d no significant interferences in the blank DBS traces were found from 
endogenous components in drug-free mice blood at the retention times of the enzalutamide, N-
desmethylenzalutamide, darolutamide, ORM-15341 and the IS indicating that the method is selective. 
Sensitivity 
The lowest limit of reliable quantification for the analyte was set at the concentration of the LLOQ. The 
precision and accuracy at LLOQ concentration were found to be 7.00 and 103 % for enzalutamide; 3.70 and 
98.0 % for N-desmethylenzalutamide; 5.25 and 95.2 % for darolutamide and 2.85 and 103 % for ORM-
15341. There was no carry-over produced by the highest calibration sample on the following injected blank 
DBS extract sample. 
Recovery 
The recovery (mean ± S.D) for enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 
(at LQC, MQC and HQC) is presented in Table 2. Recovery for the IS was 85.4 ± 5.89 %.  
Matrix effect 
Six different lots of DBS samples, spiked with analytes concentration levels at LQC and HQC levels were 
analyzed. The results have shown that the precision and accuracy for analyzed samples were within 
acceptance range (Table 2). Overall it was found that there is no impact on the ionization of analytes and 
the IS. Matrix effect for the IS was 105 ± 1.25 %. 
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Figure 2.Typical MRM chromatograms mice blank DBS (left panel), IS (middle panel) and LLOQ (right panel) 
for (a) enzalutamide (b) N-desmethylenzalutamide (c) darolutamide and (d) ORM-15341 
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Table 2. Recovery and matrix data for enzalutamide, N-desmethylenzalutamide, darolutamide and 
ORM-15341 quality controls on DBS cards 
 
Mean recovery, % 
Mean ± SD (n=4) 
Mean absolute  
matrix effect, %  
Mean ± SD (n=4) 
LQC (2.80 ng/mL) 





84.4 ± 11.0 
78.0 ± 7.83 
47.2 ± 4.55 
79.7 ± 15.4 
 
99.2 ± 5.85 
101 ± 8.58 
88.3 ± 2.34 
95.8 ± 6.23 






78.6 ± 4.50 
76.7 ± 3.75 
50.3 ± 1.99 
77.1 ± 3.32 
 
95.3 ± 12.0 
108 ± 5.68 
85.2 ± 1.35 
98.6 ± 2.38 
SD: standard deviation 
Calibration curve 
The blood calibration curve was constructed using eight calibration standards (viz., 0.93-2000 ng/mL). 
The calibration standard curve had a reliable reproducibility over the standard concentrations across the 
calibration range. Calibration curve was prepared by determining the best fit of peak-area ratios (peak area 
analyte/peak area IS) versus concentration, and fitted to the y = mx + c using weighing factor (1/X2). The 
average slope and intercept values were found to be 0.005358 and 0.002326; 0.005078 and -0.000221; 
0.00682 and 0.000485; 0.00967 and 0.000272 for enzalutamide, N-desmethylenzalutamide, darolutamide 
and ORM-15341, respectively. The average regression (n = 4) was found to be > 0.99 for all the analytes. 
The lowest concentration with the RSD <20 % was taken as LLOQ and was found to be 0.93 ng/mL. The % 
accuracy observed for the mean of back-calculated concentrations for four calibration curves was within 
86.8-114; 85.0-108; 87.1-110 and 90.9-103; while the precision (% CV) values ranged from 4.42-10.3; 5.31-
9.34; 1.60-11.5 and 1.12-9.62 for enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341, 
respectively. 
Accuracy and precision 
Accuracy and precision data for intra- and inter-day DBS samples for enzalutamide, N-
desmethylenzalutamide, darolutamide and ORM-15341 are presented in Table 3. The assay values on both 
the occasions (intra- and inter-day) were found to be within the accepted variable limits. 
Stability 
The measured concentrations for enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-
15341 at 2.80 and 1493 ng/mL were within 85-115 % of RE and <15 % RSD in a battery of stability tests viz., 
in-injector (24 h), at room temperature for 7 days, repeated three freeze/thaw cycles and freezer stability 
at -80 ± 10 °C for at least for 30 days (Table 4). 
Dilution effect  
The accuracy of the nominal concentration of the diluted DBS samples were within 5.28 % and the 
precision was 8.56 % for all the analytes, which show the ability to dilute samples up to a dilution factor of 
ten in a linear fashion. 
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Table 3. Intra- and inter-day precision and accuracy determination for determination of enzalutamide, N-






LLOQ QC (0.93 ng/mL)     
Precision (% RSD) 6.09 2.08 9.36 2.68 
Accuracy (%RE) 0.97 0.92 1.02 0.96 
LQC (2.80 ng/mL)     
Precision (% RSD) 3.24 0.18 10.2 11.7 
Accuracy (%RE) 0.90 0.96 1.09 0.96 
MQC (853 ng/mL)     
Precision (% RSD) 6.53 3.45 5.17 4.73 
Accuracy (%RE) 1.04 1.11 0.97 1.14 
HQC (1493 ng/mL)     
Precision (% RSD) 0.90 3.92 5.26 12.0 
Accuracy (%RE) 0.99 1.00 0.86 1.13 
Inter-day 
LLOQ QC (0.93 ng/mL)     
Precision (% RSD) 8.01 5.01 6.54 1.02 
Accuracy (%RE) 1.00 1.07 1.05 1.06 
LQC (2.80 ng/mL)     
Precision (% RSD) 7.54 3.29 10.8 5.25 
Accuracy (%RE) 0.96 1.04 0.96 1.02 
MQC (853 ng/mL)     
Precision (% RSD) 2.38 2.73 8.58 10.8 
Accuracy (%RE) 1.02 1.12 1.12 1.14 
HQC (1493 ng/mL)     
Precision (% RSD) 2.18 1.58 11.2 9.28 
Accuracy (%RE) 1.04 0.99 1.00 1.14 
% RSD: relative standard deviation (SD x 100/mean) 
% RE: relative error (measured value/actual value) 
 
Hematocrit effect 
The measured enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 concentrations 
were compared with the results obtained from DBS samples are given in Table 5. The % difference was 
calculated by subtracting the % relative error of Hct 25 and 45 % from % relative error of 40 % Hct which 
was taken as standard Hct value. No significant impact of Hct on accuracy was observed for all the analytes. 
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Table 4. Stability data of enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 quality 







Room temperature (7 days) 
LQC (2.80 ng/mL)     
Precision (% RSD) 2.58 7.58 5.98 7.68 
Accuracy (%RE) 0.91 0.86 0.95 0.98 
HQC (1493 ng/mL)     
Precision (% RSD) 5.84 5.68 3.56 4.89 
Accuracy (%RE) 1.02 0.95 0.98 0.86 
In-injector (24 h) 
LQC (2.80 ng/mL)     
Precision (% RSD) 6.78 0.73 7.04 4.60 
Accuracy (%RE) 0.87 0.85 0.90 0.94 
HQC (1493 ng/mL)     
Precision (% RSD) 8.58 10.3 9.08 11.0 
Accuracy (%RE) 0.95 0.86 1.00 0.87 
3 F/T cycle 
LQC (2.80 ng/mL)     
Precision (% RSD) 5.03 6.60 8.65 5.68 
Accuracy (%RE) 1.10 0.99 0.95 0.88 
HQC (1493 ng/mL)     
Precision (% RSD) 6.47 11.6 5.28 11.7 
Accuracy (%RE) 1.03 0.94 0.94 0.86 
Long-term stability at -80°C (30 days) 
LQC (2.80 ng/mL)     
Precision (% RSD) 4.77 9.21 10.2 6.60 
Accuracy (%RE) 1.01 1.02 0.91 0.89 
HQC (1493 ng/mL)     
Precision (% RSD) 4.03 8.81 10.2 4.85 
Accuracy (%RE) 1.04 0.99 0.87 0.85 
% RSD: relative standard deviation (SD x 100/mean) 
% RE: relative error (measured value/actual value) 
Pharmacokinetic study 
The sensitivity and specificity of the assay were found to be sufficient for accurately characterizing the 
pharmacokinetics of enzalutamide, N-desmethylenzalutamide (released from enzalutamide), darolutamide 
and ORM-15341 (released from darolutamide) in blood following cassette dose intravenous administration 
at 1.0 mg/kg dose of enzalutamide and darolutamide to male BalbC mice. Fig. 3a shows mean blood 
concentration-time profile for enzalutamide and it was quantified till 168 h post-dosing by intravenous 
route. However the blood concentrations for N-desmethylenzalutamide were seen just above LLOQ at 4, 8, 
24 and 48 h (ranged between 1.23-4.30 ng/mL) and below LLOQ at remaining time points hence 
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pharmacokinetic parameters are not calculated for N-desmethylenzalutamide by using this limited data. 
Fig. 3b shows mean blood concentration-time profile for darolutamide and ORM-15341, both were 
quantified till 24 and 8 h, respectively post-dosing by intravenous route. Summary of the pharmacokinetic 
profiles of enzalutamide, darolutamide and ORM-15341 after single dose intravenous administration in 
male BalbC mice were shown in Table 6. In order to validate this method the pharmacokinetics results of 
enzalutamide, darolutamide and ORM-15341 in the present study were compared with earlier reported 
pharmacokinetic parameters determined using plasma as a matrix [19] and found that good correlation 
between both measurements. This shows that DBS can be used as a promising alternative suitable to 
predict exposure of enzalutamide, darolutamide and ORM-15341. N-desmethylenzalutamide 
pharmacokinetic parameters were not calculated due to low exposure and in our earlier study we did not 
calculate N-desmethylenzalutamide pharmacokinetic parameters [19]. 
Table 5. Impact of hematocrit value of enzalutamide, N-desmethylenzalutamide, darolutamide and 
ORM-15341 on the quality control sample concentration (n = 3) 
 Concentration spiked 2.80 ng/mL 1493 ng/mL 
Concentration 
found (ng/mL) 
Hematocrit (%) 25 35 45 25 35 45 
Enzalutamide 2.63 2.53 2.79 150
6 
1561 1526 
N-Desmethylenzalutamide 2.96 3.04 2.78 155
4 
1498 1585 
Darolutamide 2.80 2.85 2.86 153
7 
1633 1583 




Enzalutamide 0.94 0.90 1.00 1.01 1.05 1.02 
N-Desmethylenzalutamide 1.06 1.09 0.99 1.04 1.00 1.06 
Darolutamide 1.00 1.02 1.02 1.03 1.09 1.06 
ORM-15341 1.10 1.09 0.91 0.98 1.07 1.00 
Precision (% 
RSD) 
Enzalutamide 3.96 2.38 5.89 10.2 7.10 9.85 
N-Desmethylenzalutamide 7.12 7.33 8.65 5.87 10.6 8.36 
Darolutamide 9.21 7.12 2.35 11.2 12.3 10.9 
ORM-15341 8.18 5.55 9.38 12.4 2.95 12.3 
 
Table 6. Pharmacokinetic parameters for enzaluatmide, daroluatmide and ORM-15341 following cassette 
dose intravenous administration to mice at 1 mg/kg 






(ng  h/mL) 
24332 1514 2214 
C0  
(ng/mL) 
1180 3042 1251 
T1/2  
(h) 
31.0 4.64 1.56 
CL  
(mL/min/kg) 
0.68 11.0 --- 
Vd  
(L/kg) 
1.84 4.42 --- 
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Figure 3. Mean blood concentration-time profile of (a) enzalutamide in mice blood following intravenous 
cassette dosing of enzalutamide and darolutamide to mice at 1.0 mg/kg; (b) darolutamide and ORM-15341 
(released from darolutamide) in mice blood following intravenous cassette dosing of enzalutamide and 
darolutamide to mice at 1.0 mg/kg. 
Discussion 
The objective of the present method was to develop and validate a new simple, rapid and sensitive DBS 
method for simultaneous quantification of enzalutamide, N-desemthylenzalutamide, darolutamide and 
ORM-15341 in mice blood and apply to a pharmacokinetic study in mice. DBS [Whatman DMPK FTA or 
AutoCollect DBS (Ahlstrom-Munksjo) cards] is increasingly becoming an important tool in preclinical drug 
development, pharmacokinetic/toxicity studies, neonatal screening, clinical pharmacology, forensic 
toxicology, doping analysis and therapeutic drug monitoring. DBS method offers several advantages like 
reduced blood/plasma/serum volume per time point, minimally invasive, ease and safety in handling, 
reduce risk of infection when compared with conventional wet sampling. It offers potential cost saving in 
storage, shipment, sample processing time (usually done at room temperature) and increase in throughput 
etc [28,29].  
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To achieve a DBS method for the first-time for second generation non-steroidal anti-androgens namely 
enzalutamide and darolutamide along with its active metabolite (N-desmethylenzalutamide and ORM-
15341, respectively) during method development different options were evaluated to optimize DBS sample 
extraction and chromatography.  
Recovery was very poor (<8 %) with organic solvents (TBME, ethyl acetate, methanol and acetonitrile) 
for all the analytes. Then combination of methanol/acetonitrile:water in various ratios were systematically 
explored. The samples extracted with acetonitrile:water (80:20; 50:50 and 20:80, v/v) have shown low 
recovery (~12 %). At 80:20, 50:50 and 20:80 methanol:water v/v ratios the recoveries ranged between 22-
32 % but not reproducible for all the analytes. Water as an extraction solvent gave good recovery for the 
analytes (~47-50 % for darolutamide and >77-84 % for rest of the analytes) and data was consistent and 
reproducible.  
In order to increase the assay precision, limit the variability between analyte(s) and the IS, to mimic the 
analyte during ionization, extraction and chromatography we have used apalutamide-d3 as an IS. To avoid 
the potentially co-eluting peaks from whole blood, which will influence the ionization efficiency of the 
analytes and the IS, the mobile phase was optimized. The attained LLOQ (0.93 ng/mL) for each analyte 
(comparable LLOQ attained with plasma earlier reported by us) was sufficient to quantify pharmacokinetic 
parameters for enzalutamide, darolutamide and ORM-15341 in a pharmacokinetic study in mice. The 
acceptable limit for both intra- and inter-day accuracy and precision is ±15 % of the nominal values for all, 
except for LLOQ QC which should be within ±20%. In this method, both intra- and inter-day accuracy and 
precision are well within this limit, indicating that the developed method is precise and accurate for the 
quantification of enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341. 
Conclusions 
We developed and validated an analytical method for the determination of enzalutamide, N-
desmethylenzalutamide, darolutamide and ORM-15341 in mice DBS samples for these second generation 
non-steroidal anti-androgens. The method is selective, linear, accurate and precise in the range of 0.93-
2000 ng/mL. The DBS samples were stable in the studied conditions and haematocrit did not influence 
enzalutamide, N-desmethylenzalutamide, darolutamide and ORM-15341 quantification. The developed 
DBS method has several advantages viz., low blood volume (25 µL), reduce the large number of animal 
usage, allows serial blood sampling from mice, useful in toxicokinetic studies etc. Further, blood samples 
having hematocrit values between 25 and 45 % demonstrated acceptable accuracy and precision in the 
quantitative measurements. The utility of this assay was demonstrated through its successful application to 
a mice pharmacokinetic study.  
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